Allarity Therapeutics Inc. (ALLR) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
24 SCHOOL ST., 2ND FLOOR BOSTON, MA 02108 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 166 | 2,029 | 19,555 | |||
| Cash and cash equivalents | 166 | 2,029 | 19,555 | |||
| Receivables | 815 | |||||
| Prepaid expense | 781 | 591 | 36 | |||
| Other current assets | 209 | 1,559 | 625 | |||
| Other undisclosed current assets | 789 | 838 | ||||
| Total current assets: | 1,971 | 4,968 | 21,054 | |||
| Noncurrent Assets | ||||||
| Finance lease, right-of-use asset, after accumulated amortization | 6 | 86 | ||||
| Property, plant and equipment | 20 | 21 | 8 | |||
| Long-term investments and receivables | 350 | |||||
| Long-term investments | 350 | |||||
| Intangible assets, net (including goodwill) | 9,871 | 9,549 | 28,135 | |||
| Intangible assets, net (excluding goodwill) | 9,871 | 9,549 | 28,135 | |||
| Total noncurrent assets: | 9,891 | 9,576 | 28,579 | |||
| TOTAL ASSETS: | 11,862 | 14,544 | 49,633 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 9,725 | 8,155 | 10,489 | |||
| Taxes payable | ✕ | ✕ | ✕ | 113 | ||
| Employee-related liabilities | ✕ | ✕ | ✕ | 1,088 | ||
| Accounts payable | 8,416 | 6,251 | 698 | |||
| Accrued liabilities | 1,309 | 1,904 | 8,590 | |||
| Debt | 250 | 2,644 | 1,000 | |||
| Derivative instruments and hedges, liabilities | 3,083 | 374 | 74 | |||
| Other undisclosed current liabilities | 1,109 | 49 | 9,156 | |||
| Total current liabilities: | 14,167 | 11,222 | 20,719 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation: | 9 | |||||
| Liabilities, other than long-term debt | 446 | 1,432 | 10,121 | |||
| Accumulated deferred investment tax credit | 1,083 | 979 | ||||
| Deferred income tax liabilities | 446 | 349 | 1,961 | |||
| Operating lease, liability | 9 | |||||
| Derivative instruments and hedges, liabilities | 7,181 | |||||
| Total noncurrent liabilities: | 446 | 1,432 | 10,130 | |||
| Total liabilities: | 14,613 | 12,654 | 30,849 | |||
| Temporary equity, carrying amount | 2,003 | |||||
| Equity | ||||||
| Equity, attributable to parent | (2,751) | (113) | 18,152 | |||
| Preferred stock | 1,742 | |||||
| Common stock | 2 | 810 | ||||
| Additional paid in capital | 90,369 | 83,156 | 84,434 | |||
| Accumulated other comprehensive loss | (411) | (721) | (600) | |||
| Accumulated deficit | (94,451) | (82,550) | (66,492) | |||
| Other undisclosed equity | 632 | |||||
| Total equity: | (2,751) | (113) | 18,784 | |||
| TOTAL LIABILITIES AND EQUITY: | 11,862 | 14,544 | 49,633 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues (Other undisclosed Revenues) | |||||
| Cost of revenue (Financing Interest Expense) | (51) | (51) | |||
| Gross profit: | (51) | (51) | |||
| Operating expenses | (17,129) | (34,463) | (26,556) | ||
| Other undisclosed operating income | 51 | 51 | |||
| Operating loss: | (17,129) | (34,463) | (26,556) | ||
| Nonoperating income (expense) | 5,311 | 16,884 | (549) | ||
| Investment income, nonoperating | 22 | (85) | (495) | ||
| Gain (loss), foreign currency transaction, before tax | 133 | (913) | (95) | ||
| Interest and debt expense | (217) | (12) | (99) | ||
| Loss from continuing operations before equity method investments, income taxes: | (12,035) | (17,591) | (27,204) | ||
| Other undisclosed income from continuing operations before income taxes | 217 | ||||
| Loss from continuing operations before income taxes: | (11,818) | (17,591) | (27,204) | ||
| Income tax expense (benefit) | (83) | 1,521 | (133) | ||
| Other undisclosed loss from continuing operations | |||||
| Loss from continuing operations: | (11,901) | (16,070) | (27,337) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (27,337) | |
| Other undisclosed net income | 12 | 689 | |||
| Net loss: | (11,901) | (16,058) | (26,648) | ||
| Other undisclosed net loss attributable to parent | |||||
| Net loss attributable to parent: | (11,901) | (16,058) | (26,648) | ||
| Preferred stock dividends and other adjustments | (8,515) | (5,947) | |||
| Other undisclosed net income available to common stockholders, basic | 5,947 | ||||
| Net loss available to common stockholders, basic: | (20,416) | (16,058) | (26,648) | ||
| Dilutive securities, effect on basic earnings per share | 2,667 | ||||
| Other undisclosed net income available to common stockholders, diluted | |||||
| Net loss available to common stockholders, diluted: | (17,749) | (16,058) | (26,648) | ||
Comprehensive Income ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net loss: | (11,901) | (16,058) | (26,648) | ||
| Other comprehensive income (loss) | (310) | 121 | 1,966 | ||
| Comprehensive loss: | (12,211) | (15,937) | (24,682) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 620 | (242) | (3,941) | ||
| Comprehensive loss, net of tax, attributable to parent: | (11,591) | (16,179) | (28,623) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.